Browsing Category
Medicine
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune…
NEW YORK - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other…
Pfizer: Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105!-->…
Pfizer: Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral…
Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in!-->…
Pfizer: Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a!-->…
Pfizer: Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real…
Truveta today announced a strategic collaboration with Pfizer to deliver new safety insights on a continuous basis, using verifiable real-world data at scale. Truveta will provide Pfizer with an unprecedented data platform for research.!-->…
Pfizer: Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of…
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and!-->…
Pfizer: Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and…
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and!-->…
Pfizer: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6…
- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for!-->…
Pfizer: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi®…
Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate the!-->…
Pfizer: Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE®…
Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus letrozole for the first-line treatment of!-->…